Factor Xa Inhibitors
Concept
Vocabulary Service
Overview
subject area of
-
2 Mechanisms of action of low molecular weight heparins and heparinoids Academic Article
-
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Academic Article
-
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer Academic Article
-
2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants Academic Article
-
4 Clinical potential of low molecular weight heparins Academic Article
-
A Replacement for Warfarin Academic Article
-
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system Academic Article
-
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery Academic Article
-
A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist. Academic Article
-
A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury Academic Article
-
A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation Academic Article
-
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers Academic Article
-
A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin Academic Article
-
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study Academic Article
-
A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2) Academic Article
-
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) Academic Article
-
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer Academic Article
-
Accumulating data on rivaroxaban for venous thromboembolism in clinical practice Academic Article
-
Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial Academic Article
-
Activated Clotting Time to Guide Heparin Dosing in Non–ST-Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Academic Article
-
Acute management of bleeding in patients on novel oral anticoagulants Academic Article
-
Advances in Antithrombotic Therapy: Novel Agents Academic Article
-
Advances in the management of venous thromboembolism. Academic Article
-
Advantages and limitations of the new anticoagulants Academic Article
-
An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition Academic Article
-
An assay to measure levels of factor Xa inhibitors in blood and plasma Academic Article
-
Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study Academic Article
-
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors Academic Article
-
Andexanet Alfa for Bleeding with Factor Xa Inhibitors Academic Article
-
Andexanet Alfa for Factor Xa Inhibitor Reversal Academic Article
-
Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban Academic Article
-
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity Academic Article
-
Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence Academic Article
-
Andexanet alfa for the treatment of hemorrhage Academic Article
-
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis Academic Article
-
Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients Academic Article
-
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Academic Article
-
Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849) Academic Article
-
Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis Academic Article
-
Anticoagulants in heart disease: current status and perspectives Academic Article
-
Anticoagulation Therapy in Children Academic Article
-
Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes Academic Article
-
Anticoagulation for Mechanical Heart Valves Academic Article
-
Antithrombotic Agents Academic Article
-
Antithrombotic Therapy in Neonates and Children Academic Article
-
Apixaban for Extended Treatment of Venous Thromboembolism Academic Article
-
Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review Academic Article
-
Apixaban in Acute Coronary Syndromes Academic Article
-
Apixaban in Patients with Atrial Fibrillation Academic Article
-
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer Academic Article
-
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement Academic Article
-
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Academic Article
-
Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials Academic Article
-
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty Academic Article
-
Assays for Measuring Rivaroxaban: Their Suitability and Limitations Academic Article
-
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes Academic Article
-
Barriers and facilitators to optimal oral anticoagulant management: a scoping review Academic Article
-
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin Academic Article
-
Beyond Unfractionated Heparin and Warfarin Academic Article
-
Bleeding Complications and Management on anticoagulant therapy Academic Article
-
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design Academic Article
-
Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery Academic Article
-
COMPASS for Vascular Surgeons Academic Article
-
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF Academic Article
-
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial Academic Article
-
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source Academic Article
-
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial Academic Article
-
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials Academic Article
-
Circulating heparin‐like anticoagulants: Case report and review of literature Academic Article
-
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study Academic Article
-
Clinical implications of reversal agents for direct oral anticoagulants Academic Article
-
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist Academic Article
-
Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients Academic Article
-
Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis Academic Article
-
Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study Academic Article
-
Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance. Academic Article
-
Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study Academic Article
-
Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy Academic Article
-
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)‐5 trial Academic Article
-
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents Academic Article
-
Dabigatran: ready for prime time? Academic Article
-
Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency Academic Article
-
Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH Academic Article
-
Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syndromes with a planned early invasive strategy Academic Article
-
Design of the rivaroxaban for heparin-induced thrombocytopenia study Academic Article
-
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation Academic Article
-
Direct Factor Xa and direct thrombin inhibitors: a clinical trial update. Academic Article
-
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies Academic Article
-
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Academic Article
-
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis Academic Article
-
Direct oral anticoagulants: evidence and unresolved issues Academic Article
-
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism Academic Article
-
Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events Academic Article
-
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease Academic Article
-
Edoxaban for the Treatment of Venous Thromboembolism in Patients with Cancer Academic Article
-
Edoxaban for treatment of venous thromboembolism in patients with cancer Academic Article
-
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial Academic Article
-
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial Academic Article
-
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty Academic Article
-
Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study Academic Article
-
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism Academic Article
-
Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state Academic Article
-
Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism Academic Article
-
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1 Academic Article
-
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis Academic Article
-
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial Academic Article
-
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial Academic Article
-
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease Academic Article
-
Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction Academic Article
-
Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor–associated major bleeding Academic Article
-
Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin Academic Article
-
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients Academic Article
-
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study Academic Article
-
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry Academic Article
-
External applicability of the COMPASS trial: the Western Denmark Heart Registry Academic Article
-
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis Academic Article
-
Factor Xa and thrombin as targets for new oral anticoagulants Academic Article
-
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism Academic Article
-
Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur Academic Article
-
Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6 Academic Article
-
Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – Bridging the River Coumarin Academic Article
-
Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy Academic Article
-
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial Academic Article
-
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source Academic Article
-
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors Academic Article
-
Gastrointestinal Bleeding With Edoxaban Versus Warfarin Academic Article
-
Global Prospective Safety Analysis of Rivaroxaban Academic Article
-
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors Academic Article
-
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease Academic Article
-
Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding Academic Article
-
Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care Academic Article
-
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source Academic Article
-
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? Academic Article
-
How can we reverse bleeding in patients on direct oral anticoagulants? Academic Article
-
How to use unfractionated heparin to treat neonatal thrombosis in clinical practice Academic Article
-
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban Academic Article
-
Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE Academic Article
-
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial Academic Article
-
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy Academic Article
-
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the
XANTUS
real‐world prospective study Academic Article
-
Incidence of intracranial bleeding in anticoagulated patients with minor head injury: a systematic review and meta-analysis of prospective studies Academic Article
-
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation Academic Article
-
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome Academic Article
-
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes Academic Article
-
Influence of the duration of fondaparinux (Arixtra®) prophylaxis in preventing venous thromboembolism following major orthopedic surgery Academic Article
-
Inhibition of Fibrin-Bound Thrombin by a Covalent Antithrombin-Heparin Complex Academic Article
-
Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex Academic Article
-
Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome Academic Article
-
Interaction of low molecular weight heparin with ketorolac Academic Article
-
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy Academic Article
-
Investigation of the Anticoagulant Mechanisms of a Covalent Antithrombin-Heparin Complex Academic Article
-
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48 Academic Article
-
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants Academic Article
-
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation Academic Article
-
Laboratory monitoring of low‐molecular‐weight heparin therapy Academic Article
-
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin Academic Article
-
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial Academic Article
-
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES Academic Article
-
Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels Academic Article
-
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials Academic Article
-
Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS Academic Article
-
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial Academic Article
-
Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review Academic Article
-
Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study Academic Article
-
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease Academic Article
-
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin Academic Article
-
Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor Academic Article
-
Management of Anticoagulation Therapy in Patients With Thromboembolism in the Context of Renal Dysfunction Academic Article
-
Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis Academic Article
-
Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex Academic Article
-
Mechanisms Responsible for Catalysis of the Inhibition of Factor Xa or Thrombin by Antithrombin Using a Covalent Antithrombin-Heparin Complex Academic Article
-
Meeting the Unmet Needs in Anticoagulant Therapy Academic Article
-
Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate? Academic Article
-
Monitoring and reversal of direct oral anticoagulants Academic Article
-
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease Academic Article
-
Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials Academic Article
-
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank Academic Article
-
New Anticoagulants for Atrial Fibrillation Academic Article
-
New Antithrombotic Drugs: Potential for Use in Oncology Academic Article
-
New aspects on treatment modalities for thromboembolic episodes Academic Article
-
New oral anticoagulants in atrial fibrillation Academic Article
-
New oral anticoagulants in development Academic Article
-
New oral anticoagulants: not quite there yet Academic Article
-
New oral anticoagulants: which one should my patient use? Academic Article
-
New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010 Academic Article
-
North America anticoagulation forum guidance on reversal of direct oral anticoagulants Academic Article
-
Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism Academic Article
-
Novel oral anticoagulants and reversal agents: Considerations for clinical development Academic Article
-
Novel paediatric anticoagulants: a review of the current literature Academic Article
-
Oral Anticoagulant Therapy Academic Article
-
Oral Apixaban for the Treatment of Acute Venous Thromboembolism Academic Article
-
Oral Direct Factor Xa Inhibitors Academic Article
-
Oral Rivaroxaban for Symptomatic Venous Thromboembolism Academic Article
-
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial Academic Article
-
Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis Academic Article
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement Academic Article
-
Oral factor Xa inhibitors and risk of subdural hematoma Academic Article
-
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement Academic Article
-
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases Academic Article
-
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials Academic Article
-
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study Academic Article
-
Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Academic Article
-
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study Academic Article
-
Overview of the New Oral Anticoagulants Academic Article
-
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry Academic Article
-
Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS
2
Score: Insights From the BRAIN-AF Trial Academic Article
-
Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for practice Academic Article
-
Pentasaccharides Academic Article
-
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy Academic Article
-
Pharmacokinetic Profile of a Low-Molecular Weight Heparin (Reviparin) in Pregnant Patients Conference Paper
-
Pharmacologic tools to reduce bleeding in surgery. Academic Article
-
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome Academic Article
-
Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose Academic Article
-
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment Academic Article
-
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery Academic Article
-
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients Academic Article
-
Potential Risk Factors Contributing to Development of Venous Thromboembolism for Total Knee Replacements Patients Prophylaxed With Rivaroxaban: A Retrospective Case-Control Study Academic Article
-
Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants Academic Article
-
Preclinical differentiation of low molecular weight heparins. Academic Article
-
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study Academic Article
-
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial Academic Article
-
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial Academic Article
-
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX‐2) Academic Article
-
Probable fondaparinux-associated bullous hemorrhagic dermatosis Academic Article
-
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism Academic Article
-
Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins Academic Article
-
Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent Academic Article
-
Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex Academic Article
-
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study Academic Article
-
Prothrombin Complex Concentrates for Intracranial Hemorrhage on Factor Xa Inhibitors Academic Article
-
Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study Academic Article
-
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome Academic Article
-
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation Academic Article
-
Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis Academic Article
-
Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention Academic Article
-
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation Academic Article
-
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD) Academic Article
-
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial Academic Article
-
Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS Academic Article
-
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation Academic Article
-
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study Academic Article
-
Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins Academic Article
-
Reply Academic Article
-
Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban Academic Article
-
Response to “Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban” Academic Article
-
Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients Academic Article
-
Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding Academic Article
-
Reversal of target-specific oral anticoagulants Academic Article
-
Reversing Anticoagulant Therapy Academic Article
-
Review: In renal impairment, apixaban reduces, or does not increase, bleeding compared with other anticoagulants Academic Article
-
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial Academic Article
-
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban Academic Article
-
Risk of recurrent venous thromboembolism according to baseline risk factor profiles Academic Article
-
Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis Academic Article
-
Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial Academic Article
-
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Academic Article
-
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial Academic Article
-
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease Academic Article
-
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease Academic Article
-
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization Academic Article
-
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios Academic Article
-
Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation Academic Article
-
Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro Academic Article
-
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial Academic Article
-
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline Academic Article
-
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source Academic Article
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness Academic Article
-
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer Academic Article
-
Rivaroxaban for prevention and treatment of venous thromboembolism Academic Article
-
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease Academic Article
-
Rivaroxaban for treatment of HIT: A riveting first experience Academic Article
-
Rivaroxaban for treatment of suspected or confirmed heparin‐induced thrombocytopenia study Academic Article
-
Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment Academic Article
-
Rivaroxaban in Peripheral Artery Disease after Revascularization Academic Article
-
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation Academic Article
-
Rivaroxaban in Stable Cardiovascular Disease Academic Article
-
Rivaroxaban in treatment refractory heparin-induced thrombocytopenia Academic Article
-
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism Academic Article
-
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial Academic Article
-
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition Academic Article
-
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers Academic Article
-
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty Academic Article
-
Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy Academic Article
-
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial Academic Article
-
Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial Academic Article
-
Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study Academic Article
-
Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial Academic Article
-
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease Academic Article
-
Rivaroxaban with or without aspirin for prevention of cardiovascular disease Academic Article
-
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial Academic Article
-
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Academic Article
-
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion Academic Article
-
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease Academic Article
-
SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery Academic Article
-
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Academic Article
-
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study Academic Article
-
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation Academic Article
-
Selective factor Xa inhibition for thromboprophylaxis Academic Article
-
Setting a standard for venous thromboembolism prophylaxis Academic Article
-
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment Academic Article
-
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease Academic Article
-
The APTT Response of Pregnant Plasma to Unfractionated Heparin Academic Article
-
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation Academic Article
-
The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War? Academic Article
-
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE Academic Article
-
The Real Decoy Academic Article
-
The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement Academic Article
-
The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig Academic Article
-
The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study Academic Article
-
The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era Academic Article
-
The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect Academic Article
-
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients Academic Article
-
The relationship between ex vivo anti-factor Xa levels and efficacy/safety of low molecular weight heparin. Academic Article
-
The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants Academic Article
-
Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin Academic Article
-
Timing of Angiography and Outcomes in High-Risk Patients With Non–ST-Segment–Elevation Myocardial Infarction Managed Invasively Academic Article
-
To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment Academic Article
-
Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding Academic Article
-
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies Academic Article
-
Treatment of bleeding complications in patients on anticoagulant therapy Academic Article
-
Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti‐factor Xa levels Academic Article
-
Urgent Need to Measure Effects of Direct Oral Anticoagulants Academic Article
-
Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children Academic Article
-
Use of selective factor Xa inhibitors in special populations. Academic Article
-
Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study Academic Article
-
Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation Academic Article
-
What Is the Future of Factor XI Inhibitors? Academic Article
-
Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation? Academic Article
-
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America Academic Article
-
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation Academic Article
-
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation Academic Article
-
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both Academic Article